---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-009573"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2025-01-21T23:59:59+00:00"
generated_at: "2026-05-27T21:59:30.591083+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Catalyst sub-licensee DyDo launches FIRDAPSE in Japan for LEMS

## Summary
- DyDo Pharma launched FIRDAPSE (amifampridine) 10 mg tablets in Japan for Lambert-Eaton myasthenic syndrome (LEMS).
- FIRDAPSE is the only U.S. FDA-approved therapy for LEMS in adults and pediatric patients 6 years and older.
- Previously approved in U.S., Europe, and Canada; Japan launch expands geographic footprint.
- Catalyst CEO Richard Daly cited commitment to health equity and increasing patient access worldwide.

## SEC filing metadata
- accession: 0001193125-25-009573
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2025-01-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312525009573/0001193125-25-009573-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312525009573/d848918d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-009573
- JSON: https://secwatch.observer/filing/0001193125-25-009573.json
- Plain text: https://secwatch.observer/filing/0001193125-25-009573.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.